February 26, 2015

Regis Looks to Extend cGMP Services to the Oncology Market

Regis Technologies announced new potent compound capabilities this month for the development of oncology drug substances. Regis Technologies is proud to announce the commissioning and start up of their new Potent Compound Suite (PCS) for 2015. Regis is a contract manufacturing organization operating a 36,000 square foot, cGMP facility in […]
October 8, 2014

Potent Compound Initiative Underway

Regis’ Potent Compound Initiative is proceeding along well. Our Analytical Team underwent training last week on how to handle potent compounds with OEL’s (occupational exposure limit) down to 0.05 micrograms/m3 safely in the analytical labs. The Potent Compound Suite is expected to be commissioned at the end of the year, […]
January 21, 2014

Regis Technologies Reports Successful FDA Audit with no Form 483 Observations

—Two Most Recent FDA Audits had no Form 483’s, Highlighting Consistency of Regis’ Quality and Regulatory Excellence— —FDA Has Recognized Regis as a Control Testing Lab, Easing Inspection Requirements for Customers— —Visit Booth #1246 at InformEx to Learn More about Regis’ Quality Services— Morton Grove, IL, January 21, 2014 – […]